Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

NCT ID: NCT00618098

Last Updated: 2023-01-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-05-31
• Study Completion Date: 2012-08-31

Brief Summary

The purpose of this study is to determine whether Octaplex (human prothrombin complex concentrate) can reverse the effects of anticoagulants when compared to the standard treatment of fresh frozen plasma (FFP).

Detailed Description

The primary objective of the study is to demonstrate that the efficacy of Octaplex as a reversal agent in patients under vitamin K antagonist therapy with the need for urgent surgery or invasive procedures was not clinically inferior to that of FFP.

The secondary objective of the study is to investigate the safety and tolerability of Octaplex compared to FFP in patients under vitamin K antagonist therapy with the need for urgent surgery or invasive procedures.

Conditions

Reversal of Anticoagulant Treatment

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Octaplex (human prothrombin complex concentrate)

Participants to receive1 or more Octaplex infusions intravenously until their International Normalized Ratio (INR) was \< 1.5.

Group Type: EXPERIMENTAL

Octaplex (human prothrombin complex concentrate)

Intervention Type: BIOLOGICAL

INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).

Fresh frozen plasma

Participants to receive1 or more fresh frozen plasma infusions intravenously until their International Normalized Ratio (INR) was \< 1.5.

Group Type: ACTIVE_COMPARATOR

Fresh frozen plasma

Intervention Type: BIOLOGICAL

INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.

Interventions

Octaplex (human prothrombin complex concentrate)

INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was \< 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).

Intervention Type: BIOLOGICAL

Fresh frozen plasma

INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of \< 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was \< 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.

Intervention Type: BIOLOGICAL

Other Intervention Names

FFP

Eligibility Criteria

Inclusion Criteria

• Male or female patients at least 18 years of age.
• Patients receiving oral anticoagulation with coumadin or warfarin derived agents.
• Patients who have need for urgent surgery or an invasive procedure up to 8 hours after admission or identification of a patient currently hospitalized, where oral or parenteral vitamin K therapy is deemed too slow in its action for reversal of coumadin or warfarin anticoagulant effects.
• Patients with an international normalized ratio (INR) of 2.0 or above.
• Patients who have given written informed consent or for whom written informed consent has been obtained from the patient's legal representative on their behalf.
• Patients able and willing to comply with the procedures laid out in the study protocol. In the case of unconscious and/or incapacitated patients, the willingness of the patient's legal representative for the patient to undergo the procedures laid out in the study protocol.

Exclusion Criteria

• Patients with a life expectancy of less than 48 hours (eg, patients with a Glasgow Coma Scale (GCS) equal to 3 or a head abbreviated injury score (AIS) of 6, patients requiring continuous inotropic or pressor support, patients status post-cardiac arrest).
• Patients with a history within the last 6 months of disseminated intravascular coagulation (DIC), or hyperfibrinolysis.
• Patients with a known congenital coagulation disorder.
• Patients with known antiphospholipid antibody syndrome or have known lupus anticoagulant antibodies.
• Patients with present or past specific factor inhibitor activity.
• Patients with thrombocytopenia of < 80,000 or a history of heparin induced thrombocytopenia (HIT).
• Patients having received heparin of any type or any non-coumadin or warfarin anticoagulant immediately prior and/or intended to be given within the first 1 hour post-infusion.
• Patients who have received vitamin K more than 3 hours prior to the infusion of study drug.
• Patients with a history of hypersensitivity to plasma-derived products.
• Pregnant or nursing women.
• Patients participating in another clinical treatment study currently or during the past 1 month prior to study inclusion.
• Patients previously enrolled in this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Octapharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wolfgang Frenzel, MD

Role: STUDY_DIRECTOR

International Medical Director

Locations

Contact Octapharma for Facility details

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

LEX-205

Identifier Type: -

Identifier Source: org_study_id